Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer - Wikidata - awgldk - TriplyDB

Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer

Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer

http://www.wikidata.org/entity/Q37369840

about

Clinical Development of the E75 Vaccine in Breast Cancer Interest of Tumor-Specific CD4 T Helper 1 Cells for Therapeutic Anticancer Vaccine Current vaccine trials in glioblastoma: a review Therapeutic cancer vaccines: past, present, and future Tumor antigen-specific monoclonal antibodies and induction of T-cell immunity The development of immunoconjugates for targeted cancer therapy Monoclonal antibodies for the treatment of cancer Restoring Lost Anti-HER-2 Th1 Immunity in Breast Cancer: A Crucial Role for Th1 Cytokines in Therapy and Prevention Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation Targeted immune therapy of ovarian cancer Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implications Intratumoral delivery of recombinant vaccinia virus encoding for ErbB2/Neu inhibits the growth of salivary gland carcinoma cells Elimination of IL-10-inducing T-helper epitopes from an IGFBP-2 vaccine ensures potent antitumor activity.Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients Poxviral-based vaccine elicits immunologic responses in prostate cancer patients.Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial Therapeutic options for HER-2 positive breast cancer: Perspectives and future directions Anti-HER2 vaccines: new prospects for breast cancer therapy Monoclonal antibodies: versatile platforms for cancer immunotherapy.Generation of more effective cancer vaccines Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape.Identification of immunogenic LY6K long peptide encompassing both CD4(+) and CD8(+) T-cell epitopes and eliciting CD4(+) T-cell immunity in patients with malignant disease Recent advances in the development of breast cancer vaccines.A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancer.The present status and future prospects of peptide-based cancer vaccines.New Immunotherapy Strategies in Breast Cancer.Immune regulation of cancer Heteroclitic serological response in esophageal and prostate cancer patients after NY-ESO-1 protein vaccination.(R)Evolutionary therapy: the potential of immunotherapy to fulfill the promise of personalized cancer treatment Differential pathways regulating innate and adaptive antitumor immune responses by particulate and soluble yeast-derived β-glucans.Immunity and immune suppression in human ovarian cancer.Therapeutic cancer vaccines and translating vaccinomics science to the global health clinic: emerging applications toward proof of concept HER2-directed therapy: current treatment options for HER2-positive breast cancer.Recruitment of regulatory T cells is correlated with hypoxia-induced CXCR4 expression, and is associated with poor prognosis in basal-like breast cancers.A multiscale systems perspective on cancer, immunotherapy, and Interleukin-12 Phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition [corrected].Adding fuel to the fire: immunogenic intensification.Therapeutic cancer vaccines: current status and moving forward.T cells sensitized with breast tumor progenitor cell vaccine have therapeutic activity against spontaneous HER2/neu tumors

P2860

Q26745440-4ADD7F89-CA51-4025-B91E-A50E6A8BF7E8 Q26782583-A521A88C-364D-4510-A1F8-7024C21B5C5F Q26828965-1BE1B2EB-20F4-4663-8C2B-58E822659203 Q26863283-0FDF4D71-B611-4E3D-BF5A-B6D821B53A6E Q27009908-C8C5A22F-5501-447E-A1BC-C7942294BE91 Q27021990-90866FB3-5B09-438D-9A07-BC73654DE2D8 Q27025966-7B189376-2FAD-4966-9421-F8E76D28F8E7 Q28067145-95107A0E-2235-4971-A15F-BF4CB1A2F249 Q28075719-21E9A91D-B8F2-46BD-BA20-611EF877A629 Q28082828-AD4AC399-532D-4C94-A58B-8B1EF4B21953 Q33621393-1B1A6C77-3D6E-49C2-8386-D1454420F82B Q33645792-80F89570-965E-4B2C-ABC5-CC5CF73CE156 Q33679779-9EE5D604-8884-444A-9983-756B02779C28 Q33718182-7813C55D-2ACB-48A0-B9DB-A0D5DA6C5DC0 Q33809528-A7012BDF-1474-4084-A41F-18D22DBCA9D8 Q33879368-A83B6BD7-B09D-4A33-B0A1-DC4F8F00BFD6 Q33991804-1B0E995F-9C9F-41A6-8B43-F64FF7A39B02 Q34023704-88E99E1F-081D-468C-9D1A-3DF0FB1D8905 Q34105959-780285A1-9845-4E2D-A9BE-94EDD677B1A7 Q34111693-7B3E934C-BA5D-4FE6-BA8E-F94760BCC4CF Q34169981-FBF3563C-64BC-4366-B79F-D904AFDF74D0 Q34194706-C7F4B8BC-7484-4215-ACA0-6C6FA60A408F Q34372937-D4C40842-A4AA-4B7B-AD0D-FD55215FFD0E Q34379303-37568D40-84E5-42D0-BFE1-61D1C65CE255 Q34412289-86260B0F-E59E-4507-943D-A136442CF067 Q34528638-7A9FFEE0-A50F-4957-9994-607E686648F7 Q34549227-ACDDEC5F-599D-4258-AABB-4A032315B688 Q34586327-9E058006-5EEF-43ED-AB5B-26C42E717B64 Q34627677-19DB8332-0703-4F5C-A069-6CE139083F80 Q34736597-7560629E-B983-488F-8466-DD9803A5FB23 Q35083249-B58C0AF9-6467-4D34-BB5E-01C2F4BAEC30 Q35138135-FA7C71E1-FA00-413C-8002-3896EF5830A3 Q35193892-1C866122-E7FD-4EF9-B32B-41B55CD7D4E6 Q35551522-73461CFD-CD1D-47FA-AC43-C99612D99DD1 Q35559050-EAE794F4-C3F5-4095-BC51-57E80F09E9A6 Q35624686-CF9F6999-57E3-4555-B8C2-3D7F51D03962 Q35836070-6E3C77B4-1859-4E8A-BB9F-022B53ED45A3 Q35886393-E86BC469-0C7C-460B-8F6F-6DBC92738262 Q35894347-AECD2CAE-3FA5-4253-BB67-F0C84C70581E Q35949083-D16DD446-5343-4D33-9468-910A90D074BA

P2860

Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer

http://www.wikidata.org/entity/Q37369840

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 31 August 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Concurrent trastuzumab and HER ...... with metastatic breast cancer

@en

Concurrent trastuzumab and HER ...... with metastatic breast cancer.

@nl

type

label

Concurrent trastuzumab and HER ...... with metastatic breast cancer

@en

Concurrent trastuzumab and HER ...... with metastatic breast cancer.

@nl

prefLabel

Concurrent trastuzumab and HER ...... with metastatic breast cancer

@en

Concurrent trastuzumab and HER ...... with metastatic breast cancer.

@nl

P1433

Q37369840-0B9AC557-AD9C-4655-BAF8-46C2C9769C1D

P1476

Q37369840-B4A66B20-50E3-419B-A3B4-01CC47D780BF

P2093

Q37369840-099B5AED-CE50-411F-A362-44F214F903F2

Q37369840-2069B866-5115-447F-B3D1-DBC4A354D0D6

Q37369840-24B47865-1F96-4F6A-AEAA-456B33D88A20

Q37369840-2B3EF2D2-D6E2-419A-8C75-ACFDB3D3E20D

Q37369840-410AF8DA-88C4-41B6-8E23-62814259A9F2

Q37369840-4EE134BB-398E-4680-8579-C72B6BF342E2

Q37369840-5643CF5F-4B11-4253-8045-E2970FEBBB9F

Q37369840-7343CE1C-901D-41EC-B598-36AFE001165C

Q37369840-99F86FD1-1123-4D40-AAE4-3743A917DD5D

Q37369840-9AD7B446-ABEB-4074-95B3-B18C0C47C1EA

P2860

Q37369840-0047482F-5BCE-43E8-97B6-C06775C8886C

Q37369840-082E4280-0A8D-4645-AE50-4F024DA85B20

Q37369840-271F9096-A279-451F-9CEB-EF6177DA2E4D

Q37369840-2B0F4E4C-B67B-45C2-9699-F70266A68F14

Q37369840-31BEA6D3-09AE-4152-AB70-E4644EC2A3E4

Q37369840-353DC0C4-CAFE-4634-8718-1158B3B29B88

Q37369840-3C0B0086-6FBC-4DBB-854B-B348B8377A4A

Q37369840-680E3827-87C0-4EF6-B6B6-C2AB68659FC3

Q37369840-68271461-BEFA-4A75-AA9C-8F4194061498

Q37369840-87B899CE-190F-4F27-811A-C366F464C115

P304

Q37369840-BFDAA554-057D-470B-BF27-6898B4DFAA3A

P31

Q37369840-B398BFFB-DDA5-4AF5-A76D-1620B1A59602

P356

Q37369840-48A8ACDA-3E2F-4FA8-9F7E-2B5A1D3FC7A9

P407

Q37369840-33C37741-3368-4D7B-994C-159107FA83FD

P433

Q37369840-49A66047-AB92-4683-BF1E-81F1A8AD304B

P478

Q37369840-4758D992-FB1B-4A57-BC85-E736B160893E

P50

Q37369840-9709E07F-04D9-44AB-B000-4E57A156C4D0

P577

Q37369840-F4EDF9AA-2A07-4997-9769-BED3BCA7560D

P698

Q37369840-AFD91FA5-92E5-416D-8FA7-0052BF467242

P921

Q37369840-20E7EB3C-8CE0-4683-A125-F381C5942167

P932

Q37369840-9A696A2D-39ED-4096-9C96-82E056D2164C

P356

JCO.2008.20.6789

P1433

Journal of Clinical Oncology

P1476

Concurrent trastuzumab and HER ...... with metastatic breast cancer

@en

P2093

Andrew L Coveler

http://www.w3.org/2001/XMLSchema#string

Corazon dela Rosa

http://www.w3.org/2001/XMLSchema#string

Danelle R Wallace

http://www.w3.org/2001/XMLSchema#string

Doreen M Higgins

http://www.w3.org/2001/XMLSchema#string

Hailing Lu

http://www.w3.org/2001/XMLSchema#string

James Waisman

http://www.w3.org/2001/XMLSchema#string

Jennifer S Childs

http://www.w3.org/2001/XMLSchema#string

John Link

http://www.w3.org/2001/XMLSchema#string

Kathleen Tietje

http://www.w3.org/2001/XMLSchema#string

Lupe G Salazar

http://www.w3.org/2001/XMLSchema#string

P2860

Autoantibody profiling for the study and treatment of autoimmune disease.

Impact of cryopreservation on tetramer, cytokine flow cytometry, and ELISPOT

Epitope spreading in immune-mediated diseases: implications for immunotherapy.

A clinical development paradigm for cancer vaccines and related biologics.

Tumor-induced immune suppression of in vivo effector T-cell priming is mediated by the B7-H1/PD-1 axis and transforming growth factor beta.

Antibody-enhanced cross-presentation of self antigen breaks T cell tolerance.

Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients

TGF-beta and tumors--an ill-fated alliance.

Antigen processing by autoreactive B cells promotes determinant spreading.

Cooperation between CD4+ and CD8+ T cells: when, where, and how.

P304

4685-4692

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2008.20.6789

http://www.w3.org/2001/XMLSchema#string

P407

P433

28

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-08-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19720923

http://www.w3.org/2001/XMLSchema#string

P921

P932

2754913

http://www.w3.org/2001/XMLSchema#string